PD-L1表达与甲状腺髓样癌临床病理特征及复发相关
该回顾性研究纳入201例连续接受初始手术的甲状腺髓样癌患者,采用免疫组化评估PD-L1表达(联合阳性评分≥1为阳性)。中位随访73个月,PD-L1阳性率14.4%,与更大肿瘤、淋巴结转移及晚期TNM分期相关,且为结构复发和生化复发/持续疾病的独立预测因素。
要点
- PD-L1阳性与更大肿瘤、淋巴结转移及晚期TNM分期相关。
- PD-L1阳性是结构复发的独立危险因素(HR=2.19,95%CI 1.01-4.77,p=0.047)。
- PD-L1阳性与生化复发/持续疾病显著相关(OR=3.16,95%CI 1.16-8.66,p=0.025)。
核心结论
- PD-L1阳性与甲状腺髓样癌侵袭性临床病理特征相关,并独立预测结构复发和生化复发/持续疾病。
- 在发生不可治愈复发(远处或不可切除局部复发)的患者中PD-L1阳性率更高。
- 靶向PD-1/PD-L1通路的免疫检查点抑制剂可能是晚期甲状腺髓样癌的潜在治疗策略。
研究设计与样本
- 采用免疫组化染色评估PD-L1表达,联合阳性评分≥1定义为阳性。
- 中位随访时间为73个月。
主要发现
- 29例(14.4%)患者PD-L1染色阳性。
- PD-L1阳性患者更可能具有更大肿瘤尺寸(p=0.002)、淋巴结转移(p=0.036)和晚期TNM分期(p=0.019)。
- PD-L1阴性与阳性组的5年结构无复发生存率分别为85.4%和57.9%(p=0.001)。
- 多因素Cox分析显示PD-L1阳性与结构复发独立相关(风险比=2.19,95%CI 1.01-4.77,p=0.047)。
- 多因素logistic分析显示PD-L1阳性与生化复发/持续疾病显著相关(优势比=3.16,95%CI 1.16-8.66,p=0.025)。
临床怎么用
- 对甲状腺髓样癌患者可考虑评估PD-L1表达,以辅助识别结构复发和生化复发/持续疾病高风险者。
- PD-L1阳性提示可能从PD-1/PD-L1免疫检查点抑制剂治疗中获益,尤其对于晚期或不可治愈复发患者。
局限性
- 为单中心回顾性研究,可能存在选择偏倚。
- PD-L1阳性定义采用联合阳性评分≥1,不同检测方法或阈值可能影响结果。
- 免疫检查点抑制剂的疗效需前瞻性临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Expression of the programmed death-ligand 1 (PD-L1) in medullary thyroid carcinoma (MTC) has been rarely reported. In this study, we evaluated PD-L1 positivity in MTC and analyzed its correlation with clinicopathological characteristics, structural recurrence (SR), and biochemical recurrence/persistent disease (BcR/BcPD). We also evaluated the prevalence of PD-L1 expression in patients developing distant or unresectable locoregional recurrence. Methods: In total, 201 consecutive MTC patients who underwent initial surgery in our institution from January 2006 to December 2015 were included. PD-L1 expression was evaluated by immunohistochemical staining and was considered positive in case of a combined positive score ≥1. The association of PD-L1 positivity with clinicopathological characteristics, structural recurrence-free survival (SRFS), and BcR/BcPD was retrospectively investigated. Results: The median follow-up length of the entire cohort was 73 months. We observed positive PD-L1 staining in 29 (14.4%) patients who were more likely to have a larger tumor size (p = 0.002), lymph node metastases (p = 0.036), and advanced TNM staging (p = 0.019). The five-year SRFS of the PD-L1-negative and PD-L1-positive groups was 85.4% and 57.9% (p = 0.001). Multivariate Cox analysis showed that PD-L1 positivity was independently associated with SR (hazard ratio = 2.19 [95% confidence interval (CI) 1.01-4.77], p = 0.047). Furthermore, multivariate logistic analysis showed that PD-L1 positivity was significantly associated with BcR/BcPD (odds ratio = 3.16 [CI 1.16-8.66], p = 0.025). During the study period, 20 patients developed distant or unresectable locoregional recurrence, among whom 8 (40%) were PD-L1 positive, which was much higher than in the entire MTC population. Conclusions: Using a large cohort of MTC patients, we demonstrate that PD-L1 positivity is associated with aggressive clinicopathological features and is independently predictive of SR and BcR/BcPD. Furthermore, a higher rate of PD-L1 expression in patients with incurable recurrence has been observed. Therefore, immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1)/PD-L1 pathway may be a potential therapeutic strategy to treat advanced MTC.
引用
- Shi X, Yu PC, Lei BW, et al. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma. Thyroid. 2019. PMID: 31328653. doi:10.1089/thy.2019.0079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。